

DIASORIN LAUNCHES ITS FIRST ONCO-HAEMATOLOGY TEST ON LIAISON IAM: THE BCR-ABL

9 December, 2014 - **Saluggia (VC) - DiaSorin (FTSE Mid Cap:DIA)** is pleased to announce that it launched the first **onco-haematology molecular diagnostic test for the qualitative detection of Chronic Myeloid Leukemia (CML)** and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) on its **LIAISON IAM**, available in the market outside the US and UK only.

The new LIAISON IAM test will offer the benefits of a **rapid** and **reliable** detection of the BCR-ABL marker in patient's blood samples and will be of primary importance for:

- diagnosis of suspected Chronic Myeloid Leukemia in patients that will then be treated with a specific targeted drug (Tyrosin kinase Inhibitors)
- diagnosis of Acute Lymphoblastic Leukemia in patients that will initiate in time the right therapy

In fact, the **BCR-ABL marker** is the genetic cause of **95% of Chronic Myeloid Leukemia (CML)** and **30%** of cases of **Acute Lymphoblastic Leukemia (ALL)**.

The detection of this marker is mandatory to make the correct diagnosis and, therefore, to implement the right treatment that is able to selectively inactivate the cancer cells.

Paul Eros, Global Vice President of Marketing Molecular DiaSorin, commented: *"This is the first in a series of assays in which DiaSorin will use our Q-LAMP molecular amplification technology to provide significant improvements in the time taken to test for haematological malignancies, whilst also improving on sensitivity and specificity. These improvements will allow treating physicians to more accurately tailor therapy to patient need"*.

Carlo Rosa, CEO of DiaSorin Group, said: *"With the launch of our first onco-haematology product we confirm our strategy of entering this new market with our LIAISON IAM technology that, thanks to its rapid and high quality results, can make the difference in the diagnosis of a leukemia, help physicians identify the right treatment and, ultimately, save a life"*.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	BCR-ABL			
Diagnosis	Qualitative detection of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia			
Business segment	Immunodiagnos	Molecular Diagnost	✓	
Potential market	n.a.			
Technology	CLIA		Extraction	
	ELISA		Amplification/Detection	✓
	RIA		HLA Typing	
Clinical Area	Infectious Disease		Infectious Disease	
	Hepatitis and Retroviruses			
	Oncology & Endocrinology			
	Bone & Mineral		Onco-hematology	✓
	Cardiac Markers			
	GI Stool Testing			

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnos

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it